Duloxetine Capsule, Delayed Release
Product Images NDC 49252-009

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 49252-009). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Inventia Healthcare Limited., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (83d4ce72 9c62 48a8 84d3 B4f20f239f70 312 1)

The packaging label for duloxetine delayed-release capsules shows three different strengths: 20 mg, 30 mg, and 60 mg. The label lists Inventia Healthcare Limited as the labeler. The capsules are intended for oral administration and are prescription drugs for human use.*

FDA Label Image

Image (83d4ce72 9c62 48a8 84d3 B4f20f239f70 312 2)

The packaging label for duloxetine delayed-release capsules shows 20 mg strength. The label includes the product name "duloxetine," strength (20 mg), dosage form as delayed-release capsules, and the labeler as Inventia Healthcare Limited. The label appears on a white and purple background with product details and is intended for oral administration.*

FDA Label Image

Image (83d4ce72 9c62 48a8 84d3 B4f20f239f70 312 3)

The image shows a white and green carton for duloxetine delayed-release capsules by Inventia Healthcare Limited. The visible strengths on the carton are 20 mg, 30 mg, and 60 mg. The label indicates oral administration.*

FDA Label Image

Image (83d4ce72 9c62 48a8 84d3 B4f20f239f70 01)

Chemical structure diagram of duloxetine hydrochloride, showing its molecular arrangement with aromatic rings, a thiophene, and an amine group as part of the molecule.*

FDA Label Image

Image (83d4ce72 9c62 48a8 84d3 B4f20f239f70 02)

A Kaplan-Meier curve comparing the proportion of patients with relapse over time, showing separate lines for duloxetine treatment and placebo groups. The x-axis represents days from randomization to relapse, and the y-axis shows the proportion of patients with relapse, illustrating the difference in relapse rates between duloxetine and placebo over approximately 200 days.*

FDA Label Image

Image (83d4ce72 9c62 48a8 84d3 B4f20f239f70 03)

A line graph depicting the proportion of patients experiencing relapse over time (days) after randomization, comparing duloxetine treatment and placebo. The x-axis represents days from randomization to relapse, and the y-axis shows the proportion of patients with relapse. The graph shows lower relapse rates for duloxetine compared to placebo over approximately 250 days.*

FDA Label Image

Image (83d4ce72 9c62 48a8 84d3 B4f20f239f70 04)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for duloxetine capsules delayed release at 20 mg and 60 mg doses compared to placebo. The graph includes lines for duloxetine 60 mg twice daily, 60 mg once daily, 20 mg once daily, and placebo, illustrating varying patient improvement rates in pain relief.*

FDA Label Image

Image (83d4ce72 9c62 48a8 84d3 B4f20f239f70 05)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for duloxetine 60 mg BID, duloxetine 60 mg QD, and placebo groups. The graph illustrates comparative patient response over increasing pain improvement percentages.*

FDA Label Image

Image (83d4ce72 9c62 48a8 84d3 B4f20f239f70 06)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for duloxetine HCl 60 mg once daily, duloxetine HCl 60 mg twice daily, and placebo. The graph shows decreasing percentages of patients improved as pain improvement thresholds increase from greater than 0% to 100%.*

FDA Label Image

Image (83d4ce72 9c62 48a8 84d3 B4f20f239f70 07)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares duloxetine HCL dosages of 120 mg, 60 mg, and 20 mg once daily with a placebo group, illustrating patient response rates at various pain improvement thresholds.*

FDA Label Image

Image (83d4ce72 9c62 48a8 84d3 B4f20f239f70 303 1)

A line graph comparing the percentage of pediatric patients aged 13 to 17 years with juvenile fibromyalgia syndrome who achieved various levels of pain relief at week 12 in a study. The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. Two lines compare duloxetine 60 mg once daily and placebo groups across different pain improvement thresholds.*

FDA Label Image

Image (83d4ce72 9c62 48a8 84d3 B4f20f239f70 08)

A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline using BOCF. It shows two lines: one for placebo and one for duloxetine 60 mg once daily, illustrating a higher improvement trend for duloxetine over placebo across various pain improvement percentages.*

FDA Label Image

Image (83d4ce72 9c62 48a8 84d3 B4f20f239f70 09)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It shows two datasets: one for placebo (cross markers) and one for duloxetine 60/120 mg once daily (diamond markers). The duloxetine line indicates higher percentages of patient improvement across most levels of pain improvement compared to placebo.*

FDA Label Image

Image (83d4ce72 9c62 48a8 84d3 B4f20f239f70 10)

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline (BOCF). It shows two curves, one for placebo and one for duloxetine (60/120 mg once daily), depicting higher patient improvement rates with duloxetine across increasing levels of pain improvement.*

FDA Label Image

Image (83d4ce72 9c62 48a8 84d3 B4f20f239f70 240 2)

Duloxetine 60 mg delayed-release capsule shown as a single soft gel cap with beige opaque body and bright yellow opaque cap. The capsule is labeled with '60 mg' on the cap and appears without any other visible text. The product is an oral prescription medication by Inventia Healthcare Limited.*

FDA Label Image

20 mg Label (83d4ce72 9c62 48a8 84d3 B4f20f239f70 11)

Label for duloxetine delayed-release capsules, USP 20 mg by Inventia Healthcare Limited. The label shows the product name, strength, and form with a small image of a green and tan capsule. It indicates a package size of 30 capsules, prescribed only by Rx. Storage instructions and manufacturer details are included along with a barcode.*

FDA Label Image

30 mg Label (83d4ce72 9c62 48a8 84d3 B4f20f239f70 12)

Label for duloxetine delayed-release capsules USP, 30 mg strength, oral dosage form. The label shows the product name, strength, and a small image of a white capsule imprinted '800 1L'. It states 30 capsules per package, prescription only, and provides storage instructions. Manufactured by Inventia Healthcare Limited in India, the label includes an NDC (49252-008-10) and a barcode.*

FDA Label Image

60 mg Label (83d4ce72 9c62 48a8 84d3 B4f20f239f70 13)

Label for Duloxetine Delayed-Release Capsules, USP 60 mg by Inventia Healthcare Limited. The label shows a blue and white capsule with '600 1L' marked. The package contains 30 capsules for oral use, prescription only. Storage instructions and barcode are also visible, with NDC 49252-009-10.*

FDA Label Image

20 mg 100 Blister (83d4ce72 9c62 48a8 84d3 B4f20f239f70 14)

Packaging label for Duloxetine Delayed-Release Capsules, USP 20 mg by Inventia Healthcare Limited. The label is for 100 unit-dose capsules (10 x 10) and displays the capsule image. It includes pharmacist dispensing instructions, storage conditions, and states that the product is Rx only. The NDC is 49252-007-57.*

FDA Label Image

30 mg 100 Blister (83d4ce72 9c62 48a8 84d3 B4f20f239f70 15)

Packaging label for Duloxetine Delayed-Release Capsules, USP 30 mg by Inventia Healthcare Limited. The label indicates a package of 100 unit-dose capsules (10 x 10), with the NDC 49252-008-57. The label includes storage instructions, pharmacist dispensing information, and a capsule image showing imprint 800 TL. Bar code and manufacturer address details are also visible.*

FDA Label Image

60 mg 100 Blister (83d4ce72 9c62 48a8 84d3 B4f20f239f70 16)

Box packaging label for Duloxetine Delayed-Release Capsules, USP 60 mg by Inventia Healthcare Limited. The label indicates 100 unit-dose capsules in a 10x10 count. The front displays a blue and white capsule image labeled "600" and "1L". Warnings about pharmacist dispensing, storage conditions, and child safety are included. The labeler and manufacturing address in Maharashtra, India, are also shown along with an NDC number 49252-009-57 and barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.